Ben Hall

Company: 2SeventyBio
Job title: Scientist, Analytical Development
Seminars:
Addressing Safety Assessment in Next Generation Products 9:45 am
• Autologous cellular therapies that incorporate gene editing require safety assays to ensure absence of aberrant transformation in final drug product • These assays include evaluating chromosomal abnormalities, IL-2 independent growth as a surrogate for malignant transformation, and changes resulting from on- or off-target editing • Challenges with these assays such as determining acceptance criteria,…Read more
day: Day Two
Addressing Safety Assessment in Next Generation Products 11:30 am
• Autologous cellular therapies that incorporate gene editing require safety assays to ensure absence of aberrant transformation in final drug product • These assays include evaluating chromosomal abnormalities, IL-2 independent growth as a surrogate for malignant transformation, and changes resulting from on- or off-target editing • Challenges with these assays such as determining acceptance criteria,…Read more
day: Day 2 Track 1 AM